NK cells for cancer immunotherapy.

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Natural killer (NK) cells possess a unique ability to eliminate cancer cells displaying specific surface markers.
• Their role as anticancer agents is supported by their capacity to augment antibody and T cell responses.
• Tumors develop resistance mechanisms against endogenous NK cell activity.

Purpose of the Study:

• To explore the potential of ex vivo-engineered NK cells as a therapeutic strategy against cancer.
• To investigate methods for enhancing NK cell antitumour activity and overcoming tumor resistance.
• To assess the role of NK cells in conjunction with targeted therapies for cancer treatment.

Main Methods:

• Ex vivo activation, expansion, and genetic modification of NK cells.
• Development of clinical-grade NK cell platforms for patient infusions.
• Engineering next-generation NK cells to enhance activation, proliferation, and tumor homing.
• Investigating NK cell-mediated killing in combination with molecularly targeted therapies.

Main Results:

• Clinical trials using infused NK cells in patients with hematological malignancies and solid tumors have shown encouraging results.
• Engineered NK cells demonstrate increased potential to overcome tumor resistance mechanisms.
• Emerging evidence suggests enhanced NK cell-mediated tumor cell killing with targeted therapies.

Conclusions:

• NK cells are potent anticancer agents, especially when enhanced through ex vivo engineering.
• NK cell-based therapies are advancing into clinical trials with promising outcomes.
• NK cells are expected to be integral to future multi-pronged cancer treatment strategies, amplifying immune responses.